AI language tools to help tumor care teams write MDT reports

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label randomized controlled study randomizes 40 junior clinicians to either use a selected large language model (LLM) to assist in writing multidisciplinary team (MDT) reports or to write reports without LLM support. The project builds on benchmark testing that identified high-performing LLMs for clinical tasks and prospectively collects diagnostic and treatment information from 20 patient cases across five cancer types. Primary outcomes include accuracy of MDT diagnostic and treatment recommendations and time spent producing MDT reports. The study is conducted at a single center and focuses on real-world workflow integration for oncologists, surgeons, radiation oncologists, radiologists, and pathologists with 3–5 years’ experience.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* A junior doctor with a practicing physician qualification certificate.
* Oncologists, surgeons, radiation oncologists, radiologists and pathologists with 3 to 5 years of clinical experience.
* Age: 25 to 33 years old, gender not limited.
* During the research period, one can participate for no less than 10 hours.
* Agree to participate in this research and sign the informed consent form.

Exclusion Criteria:

* Have participated in the previous diagnosis and treatment of any one of the 20 cases included in the study.

Where it's running

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  Guangzhou, Guangdong, China Recruiting
• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Yunfang Yu, PhD
• Email: yuyf9@mail.sysu.edu.cn
• Phone: +8613660238987

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Precision navigation to boost cancer screening participation in high-risk communities

  This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.

  Recruiting at 3 sites Hunan Cancer Hospital · Huaihua, Hunan and 2 other locations · NCT07676383

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Combination therapy using checkpoint inhibitors for advanced solid tumors

  This study is testing a new combination treatment using special antibodies for people with advanced solid tumors like lung and liver cancer to see if it can be safer and more effective than current options.

  Recruiting Phase 1/2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05187338

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.